Floatz logo

Eribulin

HER2-positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
65/ 100

Competitive context

187 Active assets in the HER2-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
Jazz Pharmaceuticals
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BB
Epirubicin
Shanghai JMT-Bio Inc.
Phase 3BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB

View all 50 →

Same molecule, other indications

Eribulin is also rated in:

Locally Recurrent Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →